Julia Wilson - Achilles Therapeutics Head Communications
| ACHL Stock | USD 0.78 0.03 4.00% |
Insider
Julia Wilson is Head Communications of Achilles Therapeutics PLC
| Address | 245 Hammersmith Road, London, United Kingdom, W6 8PW |
| Phone | 44 20 8154 4600 |
| Web | https://www.achillestx.com |
Achilles Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2461) % which means that it has lost $0.2461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4105) %, meaning that it created substantial loss on money invested by shareholders. Achilles Therapeutics' management efficiency ratios could be used to measure how well Achilles Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.45. The value of Return On Capital Employed is expected to slide to -0.62. At this time, Achilles Therapeutics' Intangibles To Total Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.03 this year, although the value of Other Assets will most likely fall to 0.95.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Troccoli | Invesco Trust For | 71 | |
| Robert Leveille | Invesco Trust For | 50 | |
| Risa LavizzoMourey | Merck Company | 66 | |
| Daniel Vandivort | Invesco Trust For | 66 | |
| Arpa Garay | Merck Company | 42 | |
| David Williams | Merck Company | 55 | |
| Andrew Schlossberg | Invesco Trust For | 46 | |
| Jeff Ginder | LSI Industries | N/A | |
| Beth Brown | Invesco Trust For | 52 | |
| CPA CPA | LSI Industries | 64 | |
| Lisa LeCointeCephas | Merck Company | 42 | |
| Jannie Oosthuizen | Merck Company | 53 | |
| Michael Prachar | LSI Industries | 55 | |
| Michael Fleming | Merck Company | 61 | |
| James Vaughn | Invesco Trust For | 75 | |
| Jennifer Mauer | Merck Company | N/A | |
| Jeffrey Davis | LSI Industries | N/A | |
| Jeffrey Kupor | Invesco Trust For | 52 | |
| Michael Klobuchar | Merck Company | 45 | |
| Anthony LaCava | Invesco Trust For | 64 | |
| Dean Li | Merck Company | 58 | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 |
Achilles Therapeutics PLC Leadership Team
Elected by the shareholders, the Achilles Therapeutics' board of directors comprises two types of representatives: Achilles Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Achilles. The board's role is to monitor Achilles Therapeutics' management team and ensure that shareholders' interests are well served. Achilles Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Achilles Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sergio Quezada, Founder Officer | ||
| Daniel Hood, General Secretary | ||
| Tariq Ahmed, Executive People | ||
| James Taylor, Chief Officer | ||
| Julia Wilson, Head Communications | ||
| Lee Stern, Vice Communications | ||
| FMEDSCI MD, Founder | ||
| Karl MD, Founder Officer | ||
| Shree Patel, Executive Operations | ||
| Iraj Ali, CEO Director | ||
| BSc FRCPath, Founder | ||
| Edward Samuel, Executive Operations | ||
| Robert Coutts, Chief Officer |
Achilles Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Achilles Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (96.11 M) | ||||
| Shares Outstanding | 41.5 M | ||||
| Shares Owned By Insiders | 6.71 % | ||||
| Shares Owned By Institutions | 50.89 % | ||||
| Number Of Shares Shorted | 37.83 K | ||||
| Price To Earning | 0.49 X | ||||
| Price To Book | 0.24 X | ||||
| EBITDA | (80.25 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Achilles Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Achilles Therapeutics' short interest history, or implied volatility extrapolated from Achilles Therapeutics options trading.
Pair Trading with Achilles Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Achilles Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Achilles Stock
| 0.66 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.53 | ELYM | Eliem Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Achilles Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Achilles Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Achilles Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Achilles Therapeutics PLC to buy it.
The correlation of Achilles Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Achilles Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Achilles Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Achilles Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Achilles Therapeutics PLC information on this page should be used as a complementary analysis to other Achilles Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Achilles Stock analysis
When running Achilles Therapeutics' price analysis, check to measure Achilles Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Achilles Therapeutics is operating at the current time. Most of Achilles Therapeutics' value examination focuses on studying past and present price action to predict the probability of Achilles Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Achilles Therapeutics' price. Additionally, you may evaluate how the addition of Achilles Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Achilles Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.74) | Return On Assets (0.25) | Return On Equity (0.41) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.